LLY
916.07
-0.02%↓
UNH
566.13
-0.87%↓
NVO
118.17
+0.23%↑
JNJ
164.55
+0.16%↑
ABBV
188.57
-1%↓
LLY
916.07
-0.02%↓
UNH
566.13
-0.87%↓
NVO
118.17
+0.23%↑
JNJ
164.55
+0.16%↑
ABBV
188.57
-1%↓
LLY
916.07
-0.02%↓
UNH
566.13
-0.87%↓
NVO
118.17
+0.23%↑
JNJ
164.55
+0.16%↑
ABBV
188.57
-1%↓
LLY
916.07
-0.02%↓
UNH
566.13
-0.87%↓
NVO
118.17
+0.23%↑
JNJ
164.55
+0.16%↑
ABBV
188.57
-1%↓
LLY
916.07
-0.02%↓
UNH
566.13
-0.87%↓
NVO
118.17
+0.23%↑
JNJ
164.55
+0.16%↑
ABBV
188.57
-1%↓
Résumé
Variation du prix de l'action
24h
Actuel
Min
77.84
Max
78.38
Recommandations | Achat Fort |
---|---|
Prévisions sur 12 Mois | +17.9 upside |
Score Technique
By Trading Central
Confiance
Strong Bullish Evidence
77.47 / 79.01 Support & Résistance
AstraZeneca PLC ADR Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
Actualités Associées
10 sept. 2024, 09:29 UTC
AstraZeneca Shares Slump After Cancer Drug Misses Key Target
DJ
Lire
25 juil. 2024, 09:17 UTC
AstraZeneca Raises Guidance After Results Beat Market Expectations -- Update
DJ
Lire
25 juil. 2024, 06:48 UTC
AstraZeneca Raises Guidance After Revenue, Earnings Beat Market Expectations
DJ
Lire
12 sept. 2024, 17:01 UTC
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update
DJ
Lire
12 sept. 2024, 11:00 UTC
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
DJ
Lire
10 sept. 2024, 13:08 UTC
AstraZeneca's Lung Cancer Drug Candidate Disappoints, Lowering Probability of FDA Approval -- Market Talk
DJ
Lire
9 sept. 2024, 07:56 UTC
Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk
DJ
Lire
5 sept. 2024, 13:00 UTC
China Detains AstraZeneca Employees Over Alleged Transport of Unapproved Drug -- WSJ
DJ
Lire
29 juil. 2024, 10:30 UTC
Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ
DJ
Lire
25 juil. 2024, 13:20 UTC
AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook -- IBD
DJ
Lire
25 juil. 2024, 09:21 UTC
AstraZeneca's Guidance Lift Is Conservative; Risks to Upside -- Market Talk
DJ
Lire
25 juil. 2024, 07:05 UTC
AstraZeneca Guidance Raise Signals Portfolio Potential -- Market Talk
DJ
Lire
25 juil. 2024, 06:06 UTC
AstraZeneca Increased Interim Dividend by 7c to $1.00
DJ
Lire
25 juil. 2024, 06:04 UTC
AstraZeneca Had Seen Core EPS Grow by Low Double-Digit to Low Teens Percentage Range
DJ
Lire
25 juil. 2024, 06:04 UTC
AstraZeneca Had Seen Total Revenue Grow by Low Double-Digit to Low Teens Percentage Range
DJ
Lire
25 juil. 2024, 06:04 UTC
AstraZeneca Sees Core EPS Growth in 2024 by Mid Teens Percentage Range At Constant Currency
DJ
Lire
25 juil. 2024, 06:04 UTC
AstraZeneca Sees Total Revenue Growth in 2024 by Mid Teens Percentage Range At Constant Currency
DJ
Lire
25 juil. 2024, 06:03 UTC
AstraZeneca Raises 2024 View
DJ
Lire
25 juil. 2024, 06:02 UTC
AstraZeneca 2Q Revenue Consensus Was $12.7B
DJ
Lire
25 juil. 2024, 06:02 UTC
AstraZeneca 2Q Core EPS Consensus Was $1.95
DJ
Lire
25 juil. 2024, 06:00 UTC
AstraZeneca PLC 2Q Adj EPS $1.98
DJ
Lire
25 juil. 2024, 06:00 UTC
AstraZeneca PLC 2Q Pretax Pft $2.4B
DJ
Lire
25 juil. 2024, 06:00 UTC
AstraZeneca PLC 2Q Rev $12.94B
DJ
Lire
25 juil. 2024, 06:00 UTC
AstraZeneca PLC 2Q Oper Pft $2.75B
DJ
Lire
25 juil. 2024, 06:00 UTC
AstraZeneca PLC 2Q Net Pft $1.93B
DJ
Lire
25 juil. 2024, 06:00 UTC
AstraZeneca PLC 2Q EPS $1.24
DJ
Lire
15 juil. 2024, 06:04 UTC
AstraZeneca: Amolyt Pharma's Hldrs Eligible to Receive $250M On Achieving Specific Milestone
DJ
Lire
15 juil. 2024, 06:04 UTC
AstraZeneca: Amolyt Pharma's Hldrs Eligible to Receive $250M On Achieving Specific Milestone
DJ
Lire
15 juil. 2024, 06:02 UTC
AstraZeneca: Acquisition Includes $800M Upfront at Deal Closing
DJ
Lire
15 juil. 2024, 06:02 UTC
AstraZeneca: Amolyt Pharma's Total Consideration of Up to $1.05B
DJ
Lire
Comparaison
Variation de prix
AstraZeneca PLC ADR prévision
Objectif de Prix
By TipRanks
Prévisions sur 12 Mois
Moyen 92.33 USD 17.9%
Haut 99 USD
Bas 86 USD
Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.
Note du Consensus
By TipRanks
Achat Fort
7 ratings
6
Achat
1
Maintien
0
Vente
Basé sur 7 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.
Score Technique
By Trading Central
Court Terme
Strong Bullish Evidence
Recent bullish events outweigh bearish events.
Moyen Terme
Strong Bearish Evidence
Bearish events outweigh bullish events.
Long Terme
No Evidence
There are no events.
Éléments financiers
$